EKF Diagnostics Holdings PLC Distribution of shares in Verici Dx plc (4208A)

TIDMEKF TIDMVRCI

RNS Number : 4208A

EKF Diagnostics Holdings PLC

24 May 2023

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Distribution of shares in Verici Dx plc

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that in accordance with the announcement dated 20 June 2022 (the "June 2022 Announcement")(1) in relation to the distribution of certain shares it held in Verici Dx plc (the "Verici Dividend Shares"), it is today writing to certain Relevant EKF Shareholders(2) who, at the record date for the distribution, held their qualifying interest in EKF via CREST (a Qualifying CREST Account).

The letter sets out instructions as to how such persons may elect to receive all of their Verici Dividend Shares by way of transfer into their Qualifying CREST Account following the expiry of the lock-up period as described in the June 2022 Announcement.

In the event that no request for transfer into a Qualifying CREST Account is made, a Relevant EKF Shareholder will automatically receive their Verici Dividend Shares in certificated form, which may take up to 10 business days from the expiry of the lock-up period.

Notes:

1. https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862

2. A Relevant EKF Shareholder is defined in the June 2022 Announcement as an EKF shareholder who was on the register at the close of business on 24 June 2022, being the record date for the distribution of the Verici Dividend Shares; only those investors who held their EKF interests via CREST at that time are eligible to elect to receive their Verici Dividend Shares into their Qualifying CREST Account.

3. If you are the holder of a Qualifying CREST Account and do not receive any correspondence regarding this matter, please contact LINK as the Company's receiving agent on the number below.

 
     EKF Diagnostics Holdings plc                                             www.ekfdiagnostics.com 
     Julian Baines, Executive Chair / Marc                                           via Walbrook PR 
      Davies, CFO 
 
     Link Group (Registrars)                         By e-mail: shareholderenquiries@linkgroup.co.uk 
                                                                                                  or 
                                                                         by telephone: 0371 664 0391 
 
                                                        Calls are charged at the standard geographic 
                                                       rate and will vary by provider. Calls outside 
                                                           the United Kingdom will be charged at the 
                                                            applicable international rate. Lines are 
                                                        open between 09:00 - 17:30, Monday to Friday 
                                                            excluding public holidays in England and 
                                                                                               Wales 
 
     Singer Capital Markets (Nominated Adviser                              Tel: +44 (0)20 7496 3000 
      & Broker) 
     Aubrey Powell / George Tzimas / Oliver 
      Platts 
 
     Walbrook PR Limited                              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
     Paul McManus / Lianne Applegarth                     Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                                 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is an AIM-listed global diagnostics business focussed on:

-- Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

-- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANSDALKDEFA

(END) Dow Jones Newswires

May 24, 2023 02:00 ET (06:00 GMT)

EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024